BioMarin
Pays vs peer median
×1.32
+32% premium
Sample
3
low confidence
Last refreshed
2026-04-13
By therapeutic area
| Therapeutic area | Premium | Deals |
|---|---|---|
| rareDisease | ×1.32 | 3 |
By stage at signing
Not enough phase-specific data (need ≥3 deals per phase).
Recent disclosed deals
| Year | Asset | Licensor | Indication | Phase | Upfront | Total |
|---|---|---|---|---|---|---|
| 2025 | Amicus Therapeutics | Amicus Therapeutics | rare diseases | approved | $4.8B | $4.8B |
| 2025 | Inozyme Pharma | Inozyme Pharma | rare diseases | preclinical | $270M | $270M |
| 2025 | Inozyme pipeline | Inozyme Pharma | rare diseases | preclinical | $270M | $270M |
| 2025 | Fabry programs | Amicus | Fabry disease | unknown | $4.8B | $4.8B |
| 2025 | Galafold (migalastat) + pipeline | Amicus Therapeutics | Fabry Disease | approved | $4.8B | $4.8B |
How this is computed
For each BioMarin deal we find the median total deal value of comparable transactions (same therapeutic area + phase, falling back to TA-only with ≥3 peers). The buyer’s deal divided by the peer median is the per-deal premium. We trim outliers, take the trimmed mean, and clamp to [0.7×, 1.5×] to reject data errors. Confidence scales with sample size.
Trimmed mean of 3 disclosed deal premiums vs. peer medians. Raw premium 1.319, clamped to [0.7, 1.5].